Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 56.26 -0.85% -0.48
APLS closed down 0.85 percent on Monday, March 18, 2024, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
8 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Flat Down Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 200 DMA Bullish -0.85%
Stochastic Buy Signal Bullish -0.85%
NR7 Range Contraction -0.85%
NR7-2 Range Contraction -0.85%
Lower Bollinger Band Walk Weakness -0.85%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 15 hours ago
200 DMA Support about 18 hours ago
Fell Below 200 DMA about 19 hours ago
Down 1% about 19 hours ago
Rose Above Previous Day's High about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Apellis Pharmaceuticals, Inc. Description

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Organ Systems Eye Inflammatory Diseases Macular Degeneration Chronic Obstructive Pulmonary Disease Pulmonary Disease Hemoglobin Autoimmune And Inflammatory Disease Complement System Acquired Hemolytic Anemia Copd Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Intravitreal Administration

Is APLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 94.75
52 Week Low 19.8301
Average Volume 1,611,262
200-Day Moving Average 56.35
50-Day Moving Average 65.00
20-Day Moving Average 63.00
10-Day Moving Average 59.35
Average True Range 2.90
RSI (14) 33.77
ADX 20.35
+DI 12.19
-DI 26.18
Chandelier Exit (Long, 3 ATRs) 63.20
Chandelier Exit (Short, 3 ATRs) 63.87
Upper Bollinger Bands 71.97
Lower Bollinger Band 54.02
Percent B (%b) 0.12
BandWidth 28.50
MACD Line -2.41
MACD Signal Line -1.51
MACD Histogram -0.9066
Fundamentals Value
Market Cap 6.67 Billion
Num Shares 119 Million
EPS -5.23
Price-to-Earnings (P/E) Ratio -10.76
Price-to-Sales 29.77
Price-to-Book 34.99
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 58.53
Resistance 3 (R3) 58.68 58.08 58.15
Resistance 2 (R2) 58.08 57.50 58.00 58.02
Resistance 1 (R1) 57.17 57.15 56.87 57.02 57.90
Pivot Point 56.57 56.57 56.42 56.49 56.57
Support 1 (S1) 55.66 55.99 55.36 55.51 54.62
Support 2 (S2) 55.06 55.64 54.98 54.50
Support 3 (S3) 54.15 55.06 54.37
Support 4 (S4) 54.00